ASG is accelerating its doctor-led mission to enhance the quality of care, deliver eye care for all, and improve quality of life across India.
Investment in R&D was Rs. 337.6 crore (8.3% of sales) for Q2 FY2023 as compared to Rs. 330 crore (8.2% of sales) for Q2 FY2022.
The core of “LANXESS Biosecurity Solutions” is a portfolio of scientifically formulated, highly effective and versatile biocidal products
The Group will continue to make proactive investments of its management resources in the life science business
Value chain collaboration aims to foster a circular ecosystem and reduce the carbon footprint of single-use surgical instruments molded in Ixef PARA.
For the half year ended September 30th, 2022 revenue from operations stood at Rs. 185.44 crore in H1 FY23, as against Rs. 219.89 crore in H1 FY22, a decrease of 15.67%
Doxycycline Capsules (RLD Oracea) had estimated annual sales of US $215 million in the US
R&D center would be doing a lot of new product generation projects, process optimization, scale-up and product life cycle management work, full synthetic labs, the kilo labs, the process safety labs, and the population lab
The company has successfully developed Methyl salicylate using Flow Chemistry and successfully erected a Flow reactor at Jhagadia plant and expects to start production from Q3 FY23
Subscribe To Our Newsletter & Stay Updated
